Alzheimer's Disease Psychosis
7
2
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 in Adults With Alzheimer's Disease Psychosis
A Food Effect Study of LY03020 in Healthy Subjects
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
Effect of Food and Age on the Pharmacokinetics of LY03017
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis